Navigation Links
YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
Date:8/10/2009

MISSISSAUGA, ON, Aug. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today announced that its wholly-owned subsidiary, YM BioSciences USA Inc. (YM-USA) has received a license from the US Department of the Treasury's Office of Foreign Assets Control (OFAC) to further develop its lead product, nimotuzumab, for patients with solid tumor cancers in the United States.

"This license from OFAC to develop nimotuzumab in any cancer indication is a major step forward in our US development program and will allow us to immediately discuss our IND submissions with the FDA to include US patients in our randomized, double-blinded lung cancer and brain metastases trials," said David Allan, Chairman and CEO of YM BioSciences. "Our development plans may also include extending some of the Phase III trials being conducted worldwide into the US. There are quantifiable physical, emotional and financial costs that result from the numerous and severe toxicities of the currently available EGFR-targeting drugs which are not evident with the administration of our drug. Nimotuzumab has been demonstrating efficacy in trials throughout the world and we are very pleased that US patients will now have the opportunity to receive the drug and that a broader group of US oncologists will gain experience with it. Our goal is to bring this therapeutic option, already approved for marketing in 18 countries, to patients in the US as rapidly as possible."

Mr. Allan added, "We have also applied to OFAC for a license to make nimotuzumab available to US patients upon marketing approval by the FDA. This is consistent with a 2009 Staff Report to the US Senate Committee on Foreign Relations (SCFR) en
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
2. Neurocrine Biosciences Reports Second Quarter 2009 Results
3. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
4. SAFC Biosciences(R) Defines Hydrolysate Components That Enhance Chinese Hamster Ovary (CHO) Cell Line Protein Production
5. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
7. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
8. Regado Biosciences Expands Medical Advisory Board
9. YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG
10. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
11. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... , , NEW YORK, Sept. 3 ... catalogue. , , Synthetic Biology: Emerging Global ... , , This Report: , ... in 2008. This is expected to increase to $2.4 billion in 2013, ...
... LAUSANNE, Switzerland, September 3 Debiopharm Group, ... with,a focus on the development of prescription drugs ... Life Sciences Award, to Dr Lluis,Quintana-Murci from the ... in the emerging field of evolutionary genetics of,infection. ...
... , , AURORA, Ontario, Sept. 3 ... announced that John Docherty, president and chief operating officer, will ... at 12:05 p.m. EDT on Wednesday, Sept. 9, at the ... will provide an overview of the Company,s leading product development ...
Cached Biology Technology:Reportlinker Adds Synthetic Biology: Emerging Global Markets Report 2Reportlinker Adds Synthetic Biology: Emerging Global Markets Report 3Reportlinker Adds Synthetic Biology: Emerging Global Markets Report 4Reportlinker Adds Synthetic Biology: Emerging Global Markets Report 5Reportlinker Adds Synthetic Biology: Emerging Global Markets Report 6Reportlinker Adds Synthetic Biology: Emerging Global Markets Report 7Reportlinker Adds Synthetic Biology: Emerging Global Markets Report 8Reportlinker Adds Synthetic Biology: Emerging Global Markets Report 9Reportlinker Adds Synthetic Biology: Emerging Global Markets Report 10Reportlinker Adds Synthetic Biology: Emerging Global Markets Report 11The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 2The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 3Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 3
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... the mechanical strength of cancer cell mucus layers provides ... suggests why some cancer cells are more resistant to ... of engineering at Northeastern University, Boston, Mass. ... protect against infection. Cancer cells, however, produce far more ...
... March, 2011 A recent special edition of the journal ... of the British Mycological Society, features a total of 76 ... cell biology movies ever published. The movies were produced by ... is a renowned researcher in the field of fungal cell ...
... A Purdue University scientist,s nanopolymer would make it easier ... of a widely used class of cancer inhibitors. ... chemistry and a member of the Purdue Center for ... can be used to determine whether cancer drugs have ...
Cached Biology News:Breaking the mucus barrier unveils cancer cell secrets 2Purdue startup hopes to change the way we test cancer drugs 2
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
... complementary RNA Spikes for the normalization and ... array printing and for protocol assessment and ... hybridization stringency and background. Normalize Cy3 and ... Oligo Spots, and complementary RNA Spikes for ...
Kit for Detection of Mitochondrial Membrane Potential...
Biology Products: